Develops therapies targeting cancer resistance mechanisms to improve treatment outcomes.
CARGO Therapeutics, Inc., a clinical-stage biotechnology company headquartered in San Mateo, California, specializes in pioneering chimeric antigen receptor (CAR) T-cell therapies tailored for cancer patients. Central to its innovative pipeline is CRG-022, an autologous CD22 CAR T-cell product designed to combat resistance mechanisms in B-cell malignancies by targeting CD22, an alternative tumor antigen expressed in these cancers.
In addition to CRG-022, CARGO Therapeutics is advancing CRG-023, a tri-specific CAR T-cell therapy aimed at targeting tumor cells through three distinct B-cell antigen targets. This approach underscores the company's commitment to developing cutting-edge therapies that can potentially enhance treatment efficacy and broaden therapeutic options for cancer patients.
Founded in 2019 under the name Syncopation Life Sciences, Inc., CARGO Therapeutics rebranded in September 2022 to better reflect its focus and vision in the biotechnology sector. Since its inception, the company has rapidly emerged as a key player in CAR T-cell therapy development, leveraging scientific innovation and strategic partnerships to drive forward its mission of advancing transformative treatments for oncology patients.